Skip to main content

DFCI Obinutuzumab and Ibrutinib Protocol # 15-283

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Dana-Farber Cancer Institute

Start Date

November 15, 2017

End Date

December 14, 2022
 

Administered By

Duke Cancer Institute

Awarded By

Dana-Farber Cancer Institute

Start Date

November 15, 2017

End Date

December 14, 2022